drugset
drugset / Trial / NCT07702279

PSTB100 Study in Healthy Adult Subjects

NCT07702279 ↗

Phase 1 Not yet recruiting 68 enrolled Prospect Therapeutics (Nanjing) Limited
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is a randomized, double-blind, placebo-controlled, dose-escalation， first-in-human clinical trial in healthy adults, designed to assess the safety, tolerability, and PK characteristics of PSTB100 tablets.

Timeline

Start
2026-07-28
Primary completion
2027-06-12
Completion
2027-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject PSTB100 Unknown 0.25 mg Oral
Subject PSTB100 Unknown 1 mg Oral
Subject PSTB100 Unknown 2 mg Oral
Subject PSTB100 Unknown 3 mg Oral
Subject PSTB100 Unknown 5 mg Oral
Subject PSTB100 Unknown 10 mg Oral
Subject PSTB100 Unknown 20 mg Oral

Indications

No indication recorded.